Evidence map›Paper›PMID 30802273›Full record

ArticlePLoS pathogens2019

PML nuclear body-residing proteins sequentially associate with HPV genome after infectious nuclear delivery.

Lucile Guion, Malgorzata Bienkowska-Haba, Stephen DiGiuseppe, Luise Florin, Martin Sapp

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 47 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Human Papilloma Virus-Infected Cells.Sub-cellular biochemistry · 2023
    Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Lucile GuionDepartment of Microbiology and Immunology, Center for Molecular and Tumor Virology, Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States of America.ORCID 0000-0001-8426-7316
Malgorzata Bienkowska-HabaDepartment of Microbiology and Immunology, Center for Molecular and Tumor Virology, Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States of America.
Stephen DiGiuseppeDepartment of Microbiology-Immunology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America.ORCID 0000-0002-9925-9850
Luise FlorinDepartment of Virology and Research Center for Immunotherapy (FZI), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.ORCID 0000-0003-4310-7329
Martin SappDepartment of Microbiology and Immunology, Center for Molecular and Tumor Virology, Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States of America.ORCID 0000-0003-3916-8890
Louisiana State University Health Sciences Center Shreveport · USJohannes Gutenberg University Mainz · DENorthwestern University · US

Funding

COBRE Center for Molecular and Tumor VirologyP30GM110703 · NIGMS · LOUISIANA STATE UNIV HSC SHREVEPORT · PI SAPP, MARTIN · 2014 to 2018
$4.8M
Immediate early events of the HPV life cycleR01CA211576 · NCI · LOUISIANA STATE UNIV HSC SHREVEPORT · PI Katarzyna Zwolinska · 2017 to 2026
$2.8M
Cell surface events of human papillomavirus type 16 and 18 infectionR01AI081809 · NIAID · LOUISIANA STATE UNIV HSC SHREVEPORT · PI SAPP, MARTIN · 2009 to 2013
$1.8M
NCI NIH HHS R01 CA211576NIAID NIH HHS R01 AI081809NIGMS NIH HHS P30 GM110703
6 · The paper itself

Abstract

Subnuclear promyelocytic leukemia (PML) nuclear bodies (NBs) are targeted by many DNA viruses after nuclear delivery. PML protein is essential for formation of PML NBs. Sp100 and Small Ubiquitin-Like Modifier (SUMO) are also permanently residing within PML NBs. Often, large DNA viruses disassemble and reorganize PML NBs to counteract their intrinsic antiviral activity and support establishment of infection. However, human papillomavirus (HPV) requires PML protein to retain incoming viral DNA in the nucleus for subsequent efficient transcription. In contrast, Sp100 was identified as a restriction factor for HPV. These findings suggested that PML NBs are important regulators of early stages of the HPV life cycle. Nuclear delivery of incoming HPV DNA requires mitosis. Viral particles are retained within membrane-bound transport vesicles throughout mitosis. The viral genome is released from transport vesicles by an unknown mechanism several hours after nuclear envelope reformation. The minor capsid protein L2 mediates intracellular transport by becoming transmembranous in the endocytic compartment. Herein, we tested our hypothesis that PML protein is recruited to incoming viral genome prior to egress from transport vesicles. High-resolution microscopy revealed that PML protein, SUMO-1, and Sp100 are recruited to incoming viral genomes, rather than viral genomes being targeted to preformed PML NBs. Differential immunofluorescent staining suggested that PML protein and SUMO-1 associated with transport vesicles containing viral particles prior to egress, implying that recruitment is likely mediated by L2 protein. In contrast, Sp100 recruitment to HPV-harboring PML NBs occurred after release of viral genomes from transport vesicles. The delayed recruitment of Sp100 is specific for HPV-associated PML NBs. These data suggest that the virus continuously resides within a protective environment until the transport vesicle breaks down in late G1 phase and imply that HPV might modulate PML NB assembly to achieve establishment of infection and the shift to viral maintenance.

Indexed as

Antigens, NuclearAutoantigensCapsid ProteinsCell NucleusGenome, ViralHumansIntranuclear Inclusion BodiesIntranuclear SpaceNuclear ProteinsPapillomaviridaePromyelocytic Leukemia ProteinSUMO-1 ProteinTranscription FactorsTumor Suppressor ProteinsVirus ReplicationAntigens, NuclearAutoantigensCapsid ProteinsNuclear ProteinsPML protein, humanPromyelocytic Leukemia ProteinSP100 protein, humanSUMO-1 ProteinTranscription FactorsTumor Suppressor Proteins

Identifiers

PMID30802273
PMCPMC6405170
OpenAlexW2917318636

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.